STARDaki:基于共识的STARD扩展版,用于标准化报告急性肾损伤诊断准确性研究
该研究通过系统文献综述识别了2025年2月前发表的122项急性肾损伤(AKI)生物标志物诊断准确性(DTA)研究,其中15项报告不充分,剩余107项中仅19项报告了采样后48小时内AKI诊断,仅16项基于QUADAS-2标准被评为高质量,且对STARD清单的依从性过低无法进行Meta分析。国际17人专家组通过改良Delphi流程就患者选择、参考标准和重测信度报告等达成共识,形成STARDaki标准,旨在推进AKI生物标志物的开发和临床应用。
要点
- 122项AKI生物标志物诊断准确性研究中,15项报告不充分,剩余107项仅19项报告了采样后48小时内AKI诊断。
- 在报告48小时内诊断的19项研究中,仅16项基于QUADAS-2标准被评为高质量。
- 研究对STARD 2015清单的依从性过低,导致无法进行Meta分析。
- 国际17人专家组通过改良Delphi流程就患者选择、参考标准和重测信度报告达成共识,补充STARD指南形成STARDaki。
- 大多数AKI生物标志物性能研究不符合STARD报告标准,导致诊断准确性估计不佳、临床适用性和普适性降低。
适用人群与场景
- 研究对象为已发表的急性肾损伤生物标志物诊断准确性研究,非直接针对急诊或ICU患者人群。
诊断标准与关键阈值
- STARDaki共识标准涵盖患者选择、参考标准和重测信度报告三个方面,具体条件与界值未在摘要中列出。
研究设计与关键结果
- 系统文献综述识别122项AKI生物标志物诊断准确性研究,其中15项报告不充分。
- 剩余107项研究中仅19项报告了采样后48小时内AKI诊断。
- 19项研究中仅16项基于QUADAS-2标准被评为高质量。
- 对STARD清单的依从性过低,无法进行Meta分析。
- 17人国际专家组通过改良Delphi流程就患者选择、参考标准和重测信度报告达成共识,形成STARDaki标准。
证据类型、等级与局限
- 证据类型:系统文献综述与改良Delphi共识。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,大多数AKI生物标志物性能研究不符合STARD报告标准,导致诊断准确性估计不佳、临床适用性和普适性降低。
- 专家组提出STARDaki标准以推进AKI生物标志物的开发和临床应用(www.stardaki.icu)。
指南或共识出处
- STARDaki:基于共识的STARD扩展版,用于标准化报告急性肾损伤诊断准确性研究(Intensive Care Med)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Biomarkers have been identified to predict, diagnose and prognosticate acute kidney injury (AKI) but existing studies are heterogenous and contradictory.
OBJECTIVE: To compare diagnostic performance of AKI biomarkers, evaluate the quality of AKI biomarker studies and to develop standards for reporting studies of diagnostic test accuracy (DTA) of AKI biomarkers.
METHODS: A systematic literature review was conducted to identify studies focusing on the diagnostic performance of AKI biomarkers published before February 2025. Retrieved DTA studies were assessed for methodological quality and completeness using the QUADAS-2 and Standards for Reporting Diagnostic Accuracy (STARD) 2015 checklists. An international 17 member expert panel was convened to agree consensus standards for AKI biomarker studies (STARDaki) via a modified Delphi process.
RESULTS: 122 DTA studies for AKI biomarkers were identified, but 15 were insufficiently reported. Of the remaining 107 studies, only 19 reported on diagnosis of AKI within 48 h of sampling. Of these studies, only 16 were considered high-quality based on the QUADAS-2 criteria. The compliance level with the STARD checklist was too low to permit meta-analysis. The expert panel agreed criteria for patient selection, reference standards, and reporting of test-retest reliability to supplement the STARD guidance for AKI biomarker studies.
CONCLUSION: Most studies examining AKI biomarker performance fail to conform to the STARD standards for reporting, leading to poor diagnostic accuracy estimates and reduced clinical applicability and generalizability. An expert panel proposed STARDaki criteria to advance the development and clinical use of AKI biomarkers ( www.stardaki.icu ).
参考来源
- Yu H, Li Y, Mo GP, et al. STARDaki: a consensus-based STARD extension for standardized reporting of diagnostic accuracy in acute kidney injury. Intensive Care Med. 2026. PMID: 42517928. doi:10.1007/s00134-026-08549-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。